Literature DB >> 23760235

Autocrine CCL3 and CCL4 induced by the oncoprotein LMP1 promote Epstein-Barr virus-triggered B cell proliferation.

Shu-Chun Tsai1, Sue-Jane Lin, Cheau-Jye Lin, Ya-Ching Chou, Jiun-Han Lin, Te-Huei Yeh, Mei-Ru Chen, Li-Min Huang, Meng-You Lu, Ya-Chi Huang, Huan-Yun Chen, Ching-Hwa Tsai.   

Abstract

Epstein-Barr virus (EBV) alters the regulation and expression of a variety of cytokines in its host cells to modulate host immune surveillance and facilitate viral persistence. Using cytokine antibody arrays, we found that, in addition to the cytokines reported previously, two chemotactic cytokines, CCL3 and CCL4, were induced in EBV-infected B cells and were expressed at high levels in all EBV-immortalized lymphoblastoid cell lines (LCLs). Furthermore, EBV latent membrane protein 1 (LMP1)-mediated Jun N-terminal protein kinase activation was responsible for upregulation of CCL3 and CCL4. Inhibition of CCL3 and CCL4 in LCLs using a short hairpin RNA approach or by neutralizing antibodies suppressed cell proliferation and caused apoptosis, indicating that autocrine CCL3 and CCL4 are required for LCL survival and growth. Importantly, significant amounts of CCL3 were detected in EBV-positive plasma from immunocompromised patients, suggesting that EBV modulates this chemokine in vivo. This study reveals the regulatory mechanism and a novel function of CCL3 and CCL4 in EBV-infected B cells. CCL3 might be useful as a therapeutic target in EBV-associated lymphoproliferative diseases and malignancies.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23760235      PMCID: PMC3754032          DOI: 10.1128/JVI.00541-13

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  47 in total

1.  The Epstein-Barr virus-encoded G protein-coupled receptor BILF1 hetero-oligomerizes with human CXCR4, scavenges Gαi proteins, and constitutively impairs CXCR4 functioning.

Authors:  Saskia Nijmeijer; Rob Leurs; Martine J Smit; Henry F Vischer
Journal:  J Biol Chem       Date:  2010-07-09       Impact factor: 5.157

2.  Immune surveillance and therapy of lymphomas driven by Epstein-Barr virus protein LMP1 in a mouse model.

Authors:  Baochun Zhang; Sven Kracker; Tomoharu Yasuda; Stefano Casola; Matthew Vanneman; Cornelia Hömig-Hölzel; Zhe Wang; Emmanuel Derudder; Shuang Li; Tirtha Chakraborty; Shane E Cotter; Shohei Koyama; Treeve Currie; Gordon J Freeman; Jeffery L Kutok; Scott J Rodig; Glenn Dranoff; Klaus Rajewsky
Journal:  Cell       Date:  2012-02-17       Impact factor: 41.582

3.  Requirement for LMP1-induced RON receptor tyrosine kinase in Epstein-Barr virus-mediated B-cell proliferation.

Authors:  Ya-Ching Chou; Sue-Jane Lin; Jean Lu; Te-Huei Yeh; Chi-Long Chen; Pei-Lun Weng; Jiun-Han Lin; Ming Yao; Ching-Hwa Tsai
Journal:  Blood       Date:  2011-06-09       Impact factor: 22.113

Review 4.  Role of the Epstein-Barr virus-encoded latent membrane protein-1, LMP1, in the pathogenesis of nasopharyngeal carcinoma.

Authors:  Mhairi A Morris; Christopher W Dawson; Lawrence S Young
Journal:  Future Oncol       Date:  2009-08       Impact factor: 3.404

5.  A pivotal role for CXCL12 signaling in HPV-mediated transformation of keratinocytes: clues to understanding HPV-pathogenesis in WHIM syndrome.

Authors:  Ken Y C Chow; Émilie Brotin; Youcef Ben Khalifa; Laetitia Carthagena; Sébastien Teissier; Anne Danckaert; Jean-Luc Galzi; Fernando Arenzana-Seisdedos; Françoise Thierry; Françoise Bachelerie
Journal:  Cell Host Microbe       Date:  2010-12-16       Impact factor: 21.023

6.  Cytokine signatures of transformed B cells with distinct Epstein-Barr virus latencies as a potential diagnostic tool for B cell lymphoma.

Authors:  Kosuke Miyauchi; Emiko Urano; Hironori Yoshiyama; Jun Komano
Journal:  Cancer Sci       Date:  2011-04-01       Impact factor: 6.716

7.  Endogenous latent membrane protein 1 in Epstein-Barr virus-infected nasopharyngeal carcinoma cells attracts T lymphocytes through upregulation of multiple chemokines.

Authors:  Hsiao-Ching Lai; Jenn-Ren Hsiao; Chaio-Wei Chen; Shih-Yi Wu; Chien-Hsun Lee; Ih-Jen Su; Kenzo Takada; Yao Chang
Journal:  Virology       Date:  2010-07-15       Impact factor: 3.616

Review 8.  Human tumor-associated viruses and new insights into the molecular mechanisms of cancer.

Authors:  D Martin; J S Gutkind
Journal:  Oncogene       Date:  2008-12       Impact factor: 9.867

9.  Epstein-Barr virus oncoprotein LMP1 mediates survivin upregulation by p53 contributing to G1/S cell cycle progression in nasopharyngeal carcinoma.

Authors:  Lili Guo; Min Tang; Lifang Yang; Lanbo Xiao; Ann M Bode; Lili Li; Zigang Dong; Ya Cao
Journal:  Int J Mol Med       Date:  2012-01-17       Impact factor: 4.101

10.  Epstein-Barr Virus latent membrane protein 1 induces Snail and epithelial-mesenchymal transition in metastatic nasopharyngeal carcinoma.

Authors:  T Horikawa; T Yoshizaki; S Kondo; M Furukawa; Y Kaizaki; J S Pagano
Journal:  Br J Cancer       Date:  2011-03-08       Impact factor: 7.640

View more
  16 in total

1.  Maintenance of Epstein-Barr Virus Latent Status by a Novel Mechanism, Latent Membrane Protein 1-Induced Interleukin-32, via the Protein Kinase Cδ Pathway.

Authors:  Kun-Yi Lai; Ya-Ching Chou; Jiun-Han Lin; Yi Liu; Kai-Min Lin; Shin-Lian Doong; Mei-Ru Chen; Te-Huei Yeh; Sue-Jane Lin; Ching-Hwa Tsai
Journal:  J Virol       Date:  2015-03-25       Impact factor: 5.103

2.  The histone lysine demethylase Kdm6b is required for activity-dependent preconditioning of hippocampal neuronal survival.

Authors:  Ranjula Wijayatunge; Liang-Fu Chen; Young May Cha; Anthony S Zannas; Christopher L Frank; Anne E West
Journal:  Mol Cell Neurosci       Date:  2014-06-28       Impact factor: 4.314

3.  Epstein-Barr virus type 2 latently infects T cells, inducing an atypical activation characterized by expression of lymphotactic cytokines.

Authors:  Carrie B Coleman; Eric M Wohlford; Nicholas A Smith; Christine A King; Julie A Ritchie; Paul C Baresel; Hiroshi Kimura; Rosemary Rochford
Journal:  J Virol       Date:  2014-12-10       Impact factor: 5.103

4.  Comprehensive characterization of tumor immune landscape following oncolytic virotherapy by single-cell RNA sequencing.

Authors:  Divya Ravirala; Guangsheng Pei; Zhongming Zhao; Xiaoliu Zhang
Journal:  Cancer Immunol Immunother       Date:  2021-10-30       Impact factor: 6.968

Review 5.  Control of CD8 T-Cell Infiltration into Tumors by Vasculature and Microenvironment.

Authors:  J David Peske; Amber B Woods; Victor H Engelhard
Journal:  Adv Cancer Res       Date:  2015-06-01       Impact factor: 6.242

Review 6.  Oncogenes and RNA splicing of human tumor viruses.

Authors:  Masahiko Ajiro; Zhi-Ming Zheng
Journal:  Emerg Microbes Infect       Date:  2014-09-03       Impact factor: 7.163

7.  Viral pre-challenge increases central nervous system inflammation after intracranial interleukin-1β injection.

Authors:  Yvonne Couch; Andrew E Davis; Inês Sá-Pereira; Sandra J Campbell; Daniel C Anthony
Journal:  J Neuroinflammation       Date:  2014-10-17       Impact factor: 8.322

8.  Difference in cytokine production and cell cycle progression induced by Epstein-Barr virus Lmp1 deletion variants in Kmh2, a Hodgkin lymphoma cell line.

Authors:  Charlotte Sueur; Julien Lupo; Philippe Mas; Patrice Morand; Véronique Boyer
Journal:  Virol J       Date:  2014-05-19       Impact factor: 4.099

9.  Stromal ETS2 Regulates Chemokine Production and Immune Cell Recruitment during Acinar-to-Ductal Metaplasia.

Authors:  Jason R Pitarresi; Xin Liu; Sudarshana M Sharma; Maria C Cuitiño; Raleigh D Kladney; Thomas A Mace; Sydney Donohue; Sunayana G Nayak; Chunjing Qu; James Lee; Sarah A Woelke; Stefan Trela; Kyle LaPak; Lianbo Yu; Joseph McElroy; Thomas J Rosol; Reena Shakya; Thomas Ludwig; Gregory B Lesinski; Soledad A Fernandez; Stephen F Konieczny; Gustavo Leone; Jinghai Wu; Michael C Ostrowski
Journal:  Neoplasia       Date:  2016-09       Impact factor: 5.715

Review 10.  Recent insights in the pathogenesis of post-transplantation lymphoproliferative disorders.

Authors:  Julie Morscio; Thomas Tousseyn
Journal:  World J Transplant       Date:  2016-09-24
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.